Mosquito-borne flaviviruses include a large group of important human medical pathogens. Several chimaeric flaviviruses have been constructed, and show potential for vaccine development. Although Japanese encephalitis virus (JEV) live vaccine SA14-14-2 has been widely used with ideal safety and efficacy profiles, no chimaeric flavivirus based on the JEV vaccine has been described to date. Based on the reverse genetic system of the JEV vaccine SA14-14-2, a novel live chimaeric flavivirus carrying the protective antigens of West Nile virus (WNV) was constructed and recovered in this study. The resulting chimaera (ChinWNV) replicated efficiently in both mammalian and mosquito cells and possessed genetic stability after in vitro serial passaging. ChinWNV exhibited a small-plaque phenotype, and its replication was significantly restricted in mouse peripheral blood and brain compared with parental WNV. Importantly, ChinWNV was highly attenuated with regard to both neurovirulence and neuroinvasiveness in mice. Furthermore, a single ChinWNV immunization stimulated robust WNV-specific adaptive immune responses in mice, conferring significant protection against lethal WNV infection. Our results demonstrate that chimaeric flaviviruses based on the JEV vaccine can serve as a powerful platform for vaccine development, and that ChinWNV represents a potential WNV vaccine candidate that merits further development.
Alonso-PadillaJ., Jiménez de OyaN., BlázquezA. B., Escribano-RomeroE., EscribanoJ. M., SaizJ. C.2011; Recombinant West Nile virus envelope protein E and domain III expressed in insect larvae protects mice against West Nile disease. Vaccine 29:1830–1835 [View Article][PubMed]
BiedenbenderR., BevilacquaJ., GreggA. M., WatsonM., DayanG.2011; Phase II, randomized, double-blind, placebo-controlled, multicenter study to investigate the immunogenicity and safety of a West Nile virus vaccine in healthy adults. J Infect Dis 203:75–84 [View Article][PubMed]
BistaM. B., BanerjeeM. K., ShinS. H., TandanJ. B., KimM. H., SohnY. M., OhrrH. C., TangJ. L., HalsteadS. B.2001; Efficacy of single-dose SA 14-14-2 vaccine against Japanese encephalitis: a case control study. Lancet 358:791–795 [View Article][PubMed]
BrayM., LaiC. J.1991; Construction of intertypic chimeric dengue viruses by substitution of structural protein genes. Proc Natl Acad Sci U S A 88:10342–10346 [View Article][PubMed]
Centers for Disease Control and Prevention (CDC)2012; West Nile virus disease and other arboviral diseases – United States, 2011. MMWR Morb Mortal Wkly Rep 61:510–514 [View Article][PubMed]
ChangD. C., LiuW. J., AnrakuI., ClarkD. C., PollittC. C., SuhrbierA., HallR. A., KhromykhA. A.2008; Single-round infectious particles enhance immunogenicity of a DNA vaccine against West Nile virus. Nat Biotechnol 26:571–577 [View Article][PubMed]
DavisB. S., ChangG. J., CroppB., RoehrigJ. T., MartinD. A., MitchellC. J., BowenR., BunningM. L.2001; West Nile virus recombinant DNA vaccine protects mouse and horse from virus challenge and expresses in vitro a noninfectious recombinant antigen that can be used in enzyme-linked immunosorbent assays. J Virol 75:4040–4047 [View Article][PubMed]
DengY. Q., DaiJ. X., JiG. H., JiangT., WangH. J., YangH. O., TanW. L., LiuR., YuM.other authors2011; A broadly flavivirus cross-neutralizing monoclonal antibody that recognizes a novel epitope within the fusion loop of E protein. PLoS ONE 6:e16059 [View Article][PubMed]
DesprèsP., CombredetC., FrenkielM. P., LorinC., BrahicM., TangyF.2005; Live measles vaccine expressing the secreted form of the West Nile virus envelope glycoprotein protects against West Nile virus encephalitis. J Infect Dis 191:207–214 [View Article][PubMed]
DurbinA. P., KarronR. A., SunW., VaughnD. W., ReynoldsM. J., PerreaultJ. R., ThumarB., MenR., LaiC. J.other authors2001; Attenuation and immunogenicity in humans of a live dengue virus type-4 vaccine candidate with a 30 nucleotide deletion in its 3′-untranslated region. Am J Trop Med Hyg 65:405–413[PubMed]
GatchalianS., YaoY., ZhouB., ZhangL., YoksanS., KellyK., NeuzilK. M., YaïchM., JacobsonJ.2008; Comparison of the immunogenicity and safety of measles vaccine administered alone or with live, attenuated Japanese encephalitis SA 14-14-2 vaccine in Philippine infants. Vaccine 26:2234–2241 [View Article][PubMed]
GuirakhooF., ZhangZ. X., ChambersT. J., DelagraveS., ArroyoJ., BarrettA. D., MonathT. P.1999; Immunogenicity, genetic stability, and protective efficacy of a recombinant, chimeric yellow fever-Japanese encephalitis virus (ChimeriVax-JE) as a live, attenuated vaccine candidate against Japanese encephalitis. Virology 257:363–372 [View Article][PubMed]
IyerA. V., PaharB., BoudreauxM. J., WakamatsuN., RoyA. F., ChouljenkoV. N., BaghianA., ApetreiC., MarxP. A., KousoulasK. G.2009; Recombinant vesicular stomatitis virus-based west Nile vaccine elicits strong humoral and cellular immune responses and protects mice against lethal challenge with the virulent West Nile virus strain LSU-AR01. Vaccine 27:893–903 [View Article][PubMed]
KumarR., TripathiP., RizviA.2009; Effectiveness of one dose of SA 14-14-2 vaccine against Japanese encephalitis. N Engl J Med 360:1465–1466 [View Article][PubMed]
LedgerwoodJ. E., PiersonT. C., HubkaS. A., DesaiN., RuckerS., GordonI. J., EnamaM. E., NelsonS., NasonM.other authors2011; A West Nile virus DNA vaccine utilizing a modified promoter induces neutralizing antibody in younger and older healthy adults in a phase I clinical trial. J Infect Dis 203:1396–1404 [View Article][PubMed]
LeeE., StocksC. E., AmbergS. M., RiceC. M., LobigsM.2000; Mutagenesis of the signal sequence of yellow fever virus prM protein: enhancement of signalase cleavage in vitro is lethal for virus production. J Virol 74:24–32 [View Article][PubMed]
LiX. F., JiangT., YuX. D., DengY. Q., ZhaoH., ZhuQ. Y., QinE. D., QinC. F.2010; RNA elements within the 5′ untranslated region of the West Nile virus genome are critical for RNA synthesis and virus replication. J Gen Virol 91:1218–1223 [View Article][PubMed]
LiebermanM. M., NerurkarV. R., LuoH., CroppB., CarrionR.Jr, de la GarzaM., CollerB. A., ClementsD., OgataS.other authors2009; Immunogenicity and protective efficacy of a recombinant subunit West Nile virus vaccine in rhesus monkeys. Clin Vaccine Immunol 16:1332–1337 [View Article][PubMed]
LimC. K., TakasakiT., KotakiA., KuraneI.2008; Vero cell-derived inactivated West Nile (WN) vaccine induces protective immunity against lethal WN virus infection in mice and shows a facilitated neutralizing antibody response in mice previously immunized with Japanese encephalitis vaccine. Virology 374:60–70 [View Article][PubMed]
MartinaB. E., van den DoelP., KorakaP., van AmerongenG., SpohnG., HaagmansB. L., ProvaciaL. B., OsterhausA. D., RimmelzwaanG. F.2011; A recombinant influenza A virus expressing domain III of West Nile virus induces protective immune responses against influenza and West Nile virus. PLoS ONE 6:e18995 [View Article][PubMed]
MinkeJ. M., SigerL., KaracaK., AustgenL., GordyP., BowenR., RenshawR. W., LoosmoreS., AudonnetJ. C., NordgrenB.2004; Recombinant canarypoxvirus vaccine carrying the prM/E genes of West Nile virus protects horses against a West Nile virus-mosquito challenge. Arch Virol Suppl.221–230[PubMed]
MonathT. P., GuirakhooF., NicholsR., YoksanS., SchraderR., MurphyC., BlumP., WoodwardS., McCarthyK.other authors2003; Chimeric live, attenuated vaccine against Japanese encephalitis (ChimeriVax-JE): phase 2 clinical trials for safety and immunogenicity, effect of vaccine dose and schedule, and memory response to challenge with inactivated Japanese encephalitis antigen. J Infect Dis 188:1213–1230 [View Article][PubMed]
NelsonM. H., WinkelmannE., MaY., XiaJ., MasonP. W., BourneN., MilliganG. N.2010; Immunogenicity of RepliVAX WN, a novel single-cycle West Nile virus vaccine. Vaccine 29:174–182 [View Article][PubMed]
PetersenL. R., CarsonP. J., BiggerstaffB. J., CusterB., BorchardtS. M., BuschM. P.2012; Estimated cumulative incidence of West Nile virus infection in US adults, 1999–2010. Epidemiol Infect 28:1–5[PubMed]
PletnevA. G., BrayM., HugginsJ., LaiC. J.1992; Construction and characterization of chimeric tick-borne encephalitis/dengue type 4 viruses. Proc Natl Acad Sci U S A 89:10532–10536 [View Article][PubMed]
PletnevA. G., BrayM., HanleyK. A., SpeicherJ., ElkinsR.2001; Tick-borne Langat/mosquito-borne dengue flavivirus chimera, a candidate live attenuated vaccine for protection against disease caused by members of the tick-borne encephalitis virus complex: evaluation in rhesus monkeys and in mosquitoes. J Virol 75:8259–8267 [View Article][PubMed]
PletnevA. G., PutnakR., SpeicherJ., WagarE. J., VaughnD. W.2002; West Nile virus/dengue type 4 virus chimeras that are reduced in neurovirulence and peripheral virulence without loss of immunogenicity or protective efficacy. Proc Natl Acad Sci U S A 99:3036–3041 [View Article][PubMed]
PletnevA. G., SwayneD. E., SpeicherJ., RumyantsevA. A., MurphyB. R.2006; Chimeric West Nile/dengue virus vaccine candidate: preclinical evaluation in mice, geese and monkeys for safety and immunogenicity. Vaccine 24:6392–6404 [View Article][PubMed]
Posadas-HerreraG., InoueS., FukeI., MurakiY., MapuaC. A., KhanA. H., ParquetM. del. C., ManabeS., TanishitaO.other authors2010; Development and evaluation of a formalin-inactivated West Nile Virus vaccine (WN-VAX) for a human vaccine candidate. Vaccine 28:7939–7946 [View Article][PubMed]
ProwT. W., ChenX., ProwN. A., FernandoG. J., TanC. S., RaphaelA. P., ChangD., RuutuM. P., JenkinsD. W.other authors2010; Nanopatch-targeted skin vaccination against West Nile Virus and Chikungunya virus in mice. Small 6:1776–1784 [View Article][PubMed]
SaminaI., KhinichY., SimanovM., MalkinsonM.2005; An inactivated West Nile virus vaccine for domestic geese-efficacy study and a summary of 4 years of field application. Vaccine 23:4955–4958 [View Article][PubMed]
Schepp-BerglindJ., LuoM., WangD., WickerJ. A., RajaN. U., HoelB. D., HolmanD. H., BarrettA. D., DongJ. Y.2007; Complex adenovirus-mediated expression of West Nile virus C, PreM, E, and NS1 proteins induces both humoral and cellular immune responses. Clin Vaccine Immunol 14:1117–1126 [View Article][PubMed]
TandanJ. B., OhrrH., SohnY. M., YoksanS., JiM., NamC. M., HalsteadS. B.2007; Single dose of SA 14-14-2 vaccine provides long-term protection against Japanese encephalitis: a case-control study in Nepalese children 5 years after immunization. Vaccine 25:5041–5045 [View Article][PubMed]
UhrlaubJ. L., BrienJ. D., WidmanD. G., MasonP. W., Nikolich-ZugichJ.2011; Repeated in vivo stimulation of T and B cell responses in old mice generates protective immunity against lethal West Nile virus encephalitis. J Immunol 186:3882–3891 [View Article][PubMed]
WidmanD. G., IshikawaT., WinkelmannE. R., InfanteE., BourneN., MasonP. W.2009; RepliVAX WN, a single-cycle flavivirus vaccine to prevent West Nile disease, elicits durable protective immunity in hamsters. Vaccine 27:5550–5553 [View Article][PubMed]
YuY.2010; Phenotypic and genotypic characteristics of Japanese encephalitis attenuated live vaccine virus SA14-14-2 and their stabilities. Vaccine 28:3635–3641 [View Article][PubMed]